BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Prime Therapeutics Release: Study Indicates a Quarter of Lung Cancer Patients Did Not Receive Pharmacogenomic Testing Prior to Start of Treatment


11/30/2012 9:07:47 AM

ST. PAUL, Minn., Nov. 30, 2012 /PRNewswire/ -- Nearly a quarter of patients taking erlotinib (Tarceva®) for treatment of advanced non-small cell lung cancer (NSCLC) did not receive the recommended pharmacogenomic (PGx) testing prior to the start of treatment, according to a new study by pharmacy benefit manager Prime Therapeutics (Prime), in collaboration with Jonas de Souza, MD, Instructor of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center. The study will be presented December 1, 2012, at the American Society of Clinical Oncology (ASCO) Quality Care Symposium in San Diego.

Guidelines released by the National Comprehensive Cancer Network (NCCN) in March 2011 and ASCO in April 2011 recommend PGx testing for tumor epidermal growth factor receptor (EGFR) mutation in NSCLC patients. The Tarceva (erlotinib) prescribing information shows erlotinib to be effective in treating NSCLC. Patients who had a negative EGFR mutation test did not receive a significant benefit in progression free survival or overall survival.

In the study, researchers reviewed medical claims for nearly 3.4 million members from four Blue Cross and Blue Shield plans to identify patients receiving erlotinib. Researchers then reviewed claims for any current procedure terminology (CPT) code indicating PGx testing in the prior 24 months. From January 1, 2011, to June 30, 2011, 125 members received erlotinib. More than 81 percent of erlotinib claims were for lung cancer, over 14 percent were for pancreatic cancer and 4 percent were for other cancers. They found 60 patients (48 percent) were new erlotinib users and 47 had a lung cancer diagnosis. Of those, 36 (76.5 percent) had a PGx CPT code claim, ranging from four days to 22 months prior.

"Understanding mutations in the cancer can help us better understand the effectiveness of treatments and develop care management programs that will have the greatest impact on the patient," said Pat Gleason, PharmD, FCCP, BCPS, director of health outcomes with Prime. "Simplifying medical coding for pharmacogenomics testing and greater use of guidelines will help us continue to improve care for lung cancer patients."

About Prime Therapeutics

At Prime Therapeutics, people are at the center of all we do and every decision we make. As a leader in pharmacy benefit management, Prime is dedicated to making it easier for our members to obtain more affordable medicines. We leverage our unique connections to deliver programs that lead to the best health outcomes.

Prime's integrated pharmacy benefit management services include claims processing, benefit plan design, network management, clinical program consultation, rebate management, formulary administration, mail-service pharmacy and specialty pharmacy.

Headquartered in St. Paul, Minn., Prime Therapeutics serves nearly 20 million people and is collectively owned by 13 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Prime has been recognized as one of the fastest-growing private companies in the nation by Inc. 5000 and as a most engaged workplace by Achievers.

For more information, visit www.primetherapeutics.com or follow @Prime_PBM on Twitter.

SOURCE Prime Therapeutics



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES